DIOS treatment led to decreased phosphorylation of PI3K, Akt, and mTOR in cutaneous melanoma cells, and immunohistochemistry revealed significantly higher p-Akt expression in the control group of tumor-bearing mice. The gene discussed is MTOR; the disease is cutaneous melanoma.